These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
240 related articles for article (PubMed ID: 16266202)
21. Atazanavir: simplicity and convenience in different scenarios. Pérez-Elías MJ Expert Opin Pharmacother; 2007 Apr; 8(5):689-700. PubMed ID: 17376023 [TBL] [Abstract][Full Text] [Related]
22. Improvement in lipid profiles in antiretroviral-experienced HIV-positive patients with hyperlipidemia after a switch to unboosted atazanavir. Sension M; Andrade Neto JL; Grinsztejn B; Molina JM; Zavala I; González-García J; Donnelly A; Phiri P; Ledesma E; McGrath D; J Acquir Immune Defic Syndr; 2009 Jun; 51(2):153-62. PubMed ID: 19346966 [TBL] [Abstract][Full Text] [Related]
23. Atazanavir: a new protease inhibitor to treat HIV infection. Musial BL; Chojnacki JK; Coleman CI Am J Health Syst Pharm; 2004 Jul; 61(13):1365-74. PubMed ID: 15287232 [TBL] [Abstract][Full Text] [Related]
27. Lopinavir/ritonavir: a review of its use in the management of HIV infection. Oldfield V; Plosker GL Drugs; 2006; 66(9):1275-99. PubMed ID: 16827606 [TBL] [Abstract][Full Text] [Related]
28. The safety, efficacy, and pharmacokinetic profile of a switch in antiretroviral therapy to saquinavir, ritonavir, and atazanavir alone for 48 weeks and a switch in the saquinavir formulation. Winston A; Mallon PW; Satchell C; MacRae K; Williams KM; Schutz M; Law M; Cooper DA; Emery S Clin Infect Dis; 2007 Jun; 44(11):1475-83. PubMed ID: 17479946 [TBL] [Abstract][Full Text] [Related]
30. [Efficacy of atazanavir in simplification regimens]. Zamora L; Gatell JM Enferm Infecc Microbiol Clin; 2008 Dec; 26 Suppl 17():14-21. PubMed ID: 20116612 [TBL] [Abstract][Full Text] [Related]
31. [Safety of atazanavir in patients with HIV and hepatitis B and/or C virus coinfection]. Rivero A; Camacho A; Pérez-Camacho I; Torre-Cisneros J Enferm Infecc Microbiol Clin; 2008 Dec; 26 Suppl 17():45-8. PubMed ID: 20116617 [TBL] [Abstract][Full Text] [Related]
32. Clinical pharmacology, efficacy and safety of atazanavir: a review. Bentué-Ferrer D; Arvieux C; Tribut O; Ruffault A; Bellissant E Expert Opin Drug Metab Toxicol; 2009 Nov; 5(11):1455-68. PubMed ID: 19863454 [TBL] [Abstract][Full Text] [Related]
33. Outcomes of switch to atazanavir-containing combination antiretroviral therapy in HIV-1-infected patients with hyperlipidemia. Lu CL; Lin YH; Wong WW; Lin HH; Ho MW; Wang NC; Hsieh SM; Sheng WH; Hung CC; Chen MY J Microbiol Immunol Infect; 2011 Aug; 44(4):258-64. PubMed ID: 21524961 [TBL] [Abstract][Full Text] [Related]
34. Dual treatment with atazanavir-ritonavir plus lamivudine versus triple treatment with atazanavir-ritonavir plus two nucleos(t)ides in virologically stable patients with HIV-1 (SALT): 48 week results from a randomised, open-label, non-inferiority trial. Perez-Molina JA; Rubio R; Rivero A; Pasquau J; Suárez-Lozano I; Riera M; Estébanez M; Santos J; Sanz-Moreno J; Troya J; Mariño A; Antela A; Navarro J; Esteban H; Moreno S; Lancet Infect Dis; 2015 Jul; 15(7):775-84. PubMed ID: 26062881 [TBL] [Abstract][Full Text] [Related]
35. Atazanavir: improving the HIV protease inhibitor class. Becker S Expert Rev Anti Infect Ther; 2003 Oct; 1(3):403-13. PubMed ID: 15482137 [TBL] [Abstract][Full Text] [Related]
36. A randomized comparative 96-week trial of boosted atazanavir versus continued boosted protease inhibitor in HIV-1 patients with abdominal adiposity. Moyle GJ; Andrade-Villanueva J; Girard PM; Antinori A; Salvato P; Bogner JR; Hay P; Santos J; Astier L; Pans M; Balogh A; Biguenet S; Antivir Ther; 2012; 17(4):689-700. PubMed ID: 22388634 [TBL] [Abstract][Full Text] [Related]
37. Efficacy and safety of boosted and unboosted atazanavir-containing antiretroviral regimens in real life: results from a multicentre cohort study. Giuntini R; Martinelli C; Ricci E; Vichi F; Gianelli E; Madeddu G; Abeli C; Palvarini L; Penco G; Marconi P; Grosso C; Pellicano G; Bonfanti P; Quirino T HIV Med; 2010 Jan; 11(1):40-5. PubMed ID: 19686438 [TBL] [Abstract][Full Text] [Related]
38. Low frequency of genotypic resistance in HIV-1-infected patients failing an atazanavir-containing regimen: a clinical cohort study. Dolling DI; Dunn DT; Sutherland KA; Pillay D; Mbisa JL; Parry CM; Post FA; Sabin CA; Cane PA; ; J Antimicrob Chemother; 2013 Oct; 68(10):2339-43. PubMed ID: 23711895 [TBL] [Abstract][Full Text] [Related]
39. Economic and health-related quality-of-life (HRQoL) comparison of lopinavir/ritonavir (LPV/r) and atazanavir plus ritonavir (ATV+RTV) based regimens for antiretroviral therapy (ART)-naïve and -experienced United Kingdom patients in 2011. Simpson KN; Baran RW; Collomb D; Beck EJ; Van de Steen O; Dietz B J Med Econ; 2012; 15(4):796-806. PubMed ID: 22563716 [TBL] [Abstract][Full Text] [Related]
40. Efficacy and safety of unboosted atazanavir in combination with lamivudine and didanosine in naive HIV type 1 patients in Senegal. Landman R; Diallo MB; Gueye NF; Kane CT; Mboup S; Fall MB; Ndiaye B; Peytavin G; Bennai Y; Benalycherif A; Girard PM; Sow PS AIDS Res Hum Retroviruses; 2010 May; 26(5):519-25. PubMed ID: 20455760 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]